Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary?

References

• Liang TJ, Block TM, McMahon BJ, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology. 2015 Dec;62(6):1893–1908.
   PubMed Web of Science ®Google Scholar
• Hu J, Cheng J, Tang L, et al. Virological basis for the cure of chronic hepatitis B. ACS Infect Dis. 2019 May 10;5(5):659–674.
   PubMed Web of Science ®Google Scholar
• Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2(10):1104–1108.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. Br Med J. 2020 Sep 1;370:m2200.
   PubMedGoogle Scholar
• Alter H, Block T, Brown N, et al. A research agenda for curing chronic hepatitis B virus infection. Hepatology. 2018 Mar;67(3):1127–1131.
   Web of Science ®Google Scholar
• Chang J, Block TM, Guo JT. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res. 2012 Dec;96(3):405–413.
   PubMed Web of Science ®Google Scholar
• Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005 Aug;79(15):9369–9380.
   PubMed Web of Science ®Google Scholar
• Niu C, Livingston CM, Li L, et al. The Smc5/6 complex restricts HBV when localized to ND10 without inducing an innate immune response and Is counteracted by the HBV X protein shortly after infection. PLoS One. 2017;12(1):e0169648.
   Web of Science ®Google Scholar
• Gish RG, Given BD, Lai CL, et al. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antiviral Res. 2015 Sep;121:47–58.
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016 Apr;64(1 Suppl):S71–S83.
   PubMedGoogle Scholar
• Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection [In process citation]. Science. 1999;284(5415):825–829.
   PubMed Web of Science ®Google Scholar
• Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014 Mar 14;343(6176):1221–1228.
   PubMed Web of Science ®Google Scholar
• Wieland SF, Spangenberg HC, Thimme R, et al. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2129–2134.
   Web of Science ®Google Scholar
• Chen Z, Diaz G, Pollicino T, et al. Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure. Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11369–E11E78.
   Web of Science ®Google Scholar
• Le Bert N, Gill US, Hong M, et al. Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic HBV infection. Gastroenterology. 2020 Aug;159(2):652–664.
   Web of Science ®Google Scholar
• Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018 Oct 1;128(10):4573–4587.
   PubMed Web of Science ®Google Scholar
• Burton AR, Pallett LJ, McCoy LE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018 Oct 1;128(10):4588–4603.
   PubMed Web of Science ®Google Scholar
• Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007 Apr;81(8):4215–4225.
   PubMed Web of Science ®Google Scholar
• Das A, Hoare M, Davies N, et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med. 2008 Sep 1;205(9):2111–2124.
   Web of Science ®Google Scholar
• Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019 May;68(5):916–927.
   PubMed Web of Science ®Google Scholar
• Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol. 2014 Dec;61(6):1212–1219.
   PubMed Web of Science ®Google Scholar
• Li H, Wu K, Tao K, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2012 Oct;56(4):1342–1351.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018 Mar;18(3):153–167.
   PubMed Web of Science ®Google Scholar
• Alfei F, Kanev K, Hofmann M, et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019 Jul;571(7764):265–269.
   PubMed Web of Science ®Google Scholar
• Fisicaro P, Barili V, Montanini B, et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med. 2017 Mar;23(3):327–336.
   PubMed Web of Science ®Google Scholar
• Peppa D, Gill US, Reynolds G, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med. 2013 Jan 14;210(1):99–114.
   PubMed Web of Science ®Google Scholar
• Lopes AR, Kellam P, Das A, et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest. 2008 May;118(5):1835–1845.
   Web of Science ®Google Scholar
• Pallett LJ, Gill US, Quaglia A, et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med. 2015 Jun;21(6):591–600.
   PubMed Web of Science ®Google Scholar
• Sandalova E, Laccabue D, Boni C, et al. Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology. 2012 Jul;143(1):78–87e3.
   Web of Science ®Google Scholar
• Fisicaro P, Valdatta C, Massari M, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010 Feb;138(2):682–693. 93 e1-4.
   PubMed Web of Science ®Google Scholar
• Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019 Nov;18(11):827–844.
   PubMed Web of Science ®Google Scholar
• Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol. 2019 Nov;71(5):900–907.
   PubMed Web of Science ®Google Scholar
• Isogawa M, Chung J, Murata Y, et al. CD40 activation rescues antiviral CD8(+) T cells from PD-1-mediated exhaustion. PLoS Pathog. 2013;9(7):e1003490.
   Web of Science ®Google Scholar
• Boni C, Vecchi A, Rossi M, et al. TLR7 agonist Increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)Ide analogues. Gastroenterology. 2018 May;154(6):1764–77e7.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Sammons MA, Odorizzi PM, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016 Dec 2;354(6316):1160–1165.
   PubMed Web of Science ®Google Scholar
• Heim K, Neumann-Haefelin C, Thimme R, et al. Heterogeneity of HBV-specific CD8(+) T-cell failure: implications for immunotherapy. Front Immunol. 2019;10:2240.
   Web of Science ®Google Scholar
• Ghoneim HE, Fan Y, Moustaki A, et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell. 2017 Jun 29;170(1):142–157e19.
   PubMed Web of Science ®Google Scholar
• Kim JH, Ghosh A, Ayithan N, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients. Sci Rep. 2020 Feb 4;10(1):1835.
   Web of Science ®Google Scholar
• Loggi E, Bihl FK, Cursaro C, et al. Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. PLoS One. 2013;8(6):e65327.
   Web of Science ®Google Scholar
• Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012 Oct;143(4):963–973e9.
   PubMed Web of Science ®Google Scholar
• Huang Q, Zhou B, Cai D, et al. Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients. Hepatology. 2020 Jan;73(1):41–52.
   Web of Science ®Google Scholar
• Micco L, Peppa D, Loggi E, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol. 2013 Feb;58(2):225–233.
   PubMed Web of Science ®Google Scholar
• Xu X, Shang Q, Chen X, et al. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol Immunol. 2015 May;12(3):309–316.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang D, Dou X, et al. Consensus on pegylated interferon alpha in treatment of chronic hepatitis B. J Clin Transl Hepatol. 2018 Mar 28;6(1):1–10.
   PubMed Web of Science ®Google Scholar
• van den Berg F, Limani SW, Mnyandu N, et al. Advances with RNAi-based therapy for hepatitis B virus infection. Viruses. 2020 Aug 4;12(8):851.
   PubMed Web of Science ®Google Scholar
• Billioud G, Kruse RL, Carrillo M, et al. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides. J Hepatol. 2016 Apr;64(4):781–789.
   PubMed Web of Science ®Google Scholar
• Mueller H, Wildum S, Luangsay S, et al. A novel orally available small molecule that inhibits hepatitis B virus expression. J Hepatol. 2018 Mar;68(3):412–420.
   Web of Science ®Google Scholar
• Guidotti LG, Matzke B, Schaller H, et al. High-level hepatitis B virus replication in transgenic mice. J Virol. 1995;69(10):6158–6169.
   PubMed Web of Science ®Google Scholar
• McFadden VC, Shalaby RE, Iram S, et al. Hepatic deficiency of the pioneer transcription factor FoxA restricts hepatitis B virus biosynthesis by the developmental regulation of viral DNA methylation. PLoS Pathog. 2017 Feb;13(2):e1006239.
   Web of Science ®Google Scholar
• Benechet AP, De Simone G, Di Lucia P, et al. Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming. Nature. 2019 Oct;574(7777):200–205.
   PubMed Web of Science ®Google Scholar
• Thomsen MK, Nandakumar R, Stadler D, et al. Lack of immunological DNA sensing in hepatocytes facilitates hepatitis B virus infection. Hepatology. 2016 Sep;64(3):746–759.
   PubMed Web of Science ®Google Scholar
• Dion S, Bourgine M, Godon O, et al. Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J Virol. 2013 May;87(10):5554–5563.
   Web of Science ®Google Scholar
• Qi Z, Li G, Hu H, et al. Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice. J Virol. 2014 Jul;88(14):8045–8056.
   PubMed Web of Science ®Google Scholar
• Fumagalli V, Di Lucia P, Venzin V, et al. Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. J Exp Med. 2020 Nov 2;217(11):e20200298.
   Web of Science ®Google Scholar
• Kawashima K, Isogawa M, Onishi M, et al. Restoration of type I interferon signaling in intrahepatically primed CD8+ T cells promotes functional differentiation. JCI Insight. 2021 Feb 8;6(3):e145761.
   Web of Science ®Google Scholar
• Michler T, Kosinska AD, Festag J, et al. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology. 2020 May;158(6):1762–75e9.
   PubMed Web of Science ®Google Scholar
• Zhu D, Liu L, Yang D, et al. Clearing persistent extracellular antigen of hepatitis B virus: an immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination. J Immunol. 2016 Apr 1;196(7):3079–3087.
   PubMed Web of Science ®Google Scholar
• Menne S, Cote PJ. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol. 2007 Jan 7;13(1):104–124.
   Web of Science ®Google Scholar
• Menne S, Tumas DB, Liu KH, et al. Sustained efficacy and seroconversion with the toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B. J Hepatol. 2015 Jun;62(6):1237–1245.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Lim YS, Gordon SC, et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015 Aug;63(2):320–328.
   PubMed Web of Science ®Google Scholar
• Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology. 2013 Jun;144(7):1508–1517. 17 e1-10.
   PubMed Web of Science ®Google Scholar
• Zhou T, Block T, Liu F, et al. HBsag mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element. Antiviral Res. 2018 Jan;149:191–201.
   PubMed Web of Science ®Google Scholar
• Menne S, Wildum S, Steiner G, et al. Efficacy of an inhibitor of hepatitis B virus expression in combination With entecavir and interferon-alpha in woodchucks chronically infected With woodchuck hepatitis virus. Hepatol Commun. 2020 Jun;4(6):916–931.
   PubMed Web of Science ®Google Scholar
• Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013 May;21(5):973–985.
   PubMed Web of Science ®Google Scholar
• Wooddell CI, Yuen MF, Chan HL, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. 2017 Sep 27;9(409):eaan0241.
   PubMed Web of Science ®Google Scholar
• Han K, Cremer J, Elston R, et al. A randomized, double-blind, placebo-controlled, first-time-in-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects. Clin Pharmacol Drug Dev. 2019 Aug;8(6):790–801.
   PubMed Web of Science ®Google Scholar
• Vaillant A. Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Antiviral Res. 2016 Jul 9;133:32–40.
   PubMed Web of Science ®Google Scholar
• Noordeen F, Scougall CA, Grosse A, et al. Therapeutic antiviral effect of the Nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLoS One. 2015;10(11):e0140909.
   PubMed Web of Science ®Google Scholar
• Boulon R, Blanchet M, Lemasson M, et al. Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro. Antiviral Res. 2020 Nov;183:104853.
   PubMed Web of Science ®Google Scholar
• Bazinet M, Pantea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy. Gastroenterology. 2020 Jun;158(8):2180–2194.
   PubMed Web of Science ®Google Scholar
• Corti D, Benigni F, Shouval D. Viral envelope-specific antibodies in chronic hepatitis B virus infection. Curr Opin Virol. 2018 Jun;30:48–57.
   Web of Science ®Google Scholar
• Neumann AU, Phillips S, Levine I, et al. Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology. 2010 Sep;52(3):875–885.
   PubMed Web of Science ®Google Scholar
• Li D, He W, Liu X, et al. A potent human neutralizing antibody Fc-dependently reduces established HBV infections. eLife. 2017 Sep 26;6:e26738.
   PubMed Web of Science ®Google Scholar
• Zhang TY, Yuan Q, Zhao JH, et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut. 2016 Apr;65(4):658–671.
   PubMed Web of Science ®Google Scholar
• Hehle V, Beretta M, Bourgine M, et al. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. J Exp Med. 2020 Oct 5;217(10):e20200840.
   Web of Science ®Google Scholar
• Wang Q, Michailidis E, Yu Y, et al. A combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations. Cell Host Microbe. 2020 Aug 12;28(2):335–349e6.
   Web of Science ®Google Scholar
• Shi B, Wu Y, Wang C, et al. Evaluation of antiviral - passive - active immunization (“sandwich”) therapeutic strategy for functional cure of chronic hepatitis B in mice. EBioMedicine. 2019 Nov;49:247–257.
   Web of Science ®Google Scholar
• Galun E, Eren R, Safadi R, et al. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology. 2002 Mar;35(3):673–679.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Corti D, Virgin HW, et al. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature. 2020 Dec;588(7838):485–490.
   PubMed Web of Science ®Google Scholar
• Fisicaro P, Barili V, Rossi M, et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches. Front Immunol. 2020;11:849.
   PubMed Web of Science ®Google Scholar